[Irritable bowel syndrome--role of motility inhibitors].
Holtmann
G
G
Universitätsklinikum Essen, Medizinische Klinik und Poliklinik, Abteilung für Gastroenterologie und Hepatologie, Hufelandstrasse 55, 45122 Essen.
Gschossmann
J
J
Kruis
W
W
D000930:Antidiarrheals / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000503:physiopathology; D004043:Dietary Fiber / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013501:Surface-Active Agents / Q000627:therapeutic use
D000930:Antidiarrheals; D018680:Cholinergic Antagonists; D004043:Dietary Fiber; D018492:Dopamine Antagonists; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D012702:Serotonin Antagonists; D013501:Surface-Active Agents